Study | Patients excluded | Number of patients included in analysis | AuROC sensitivity analysis | AuROC primary analysis |
---|---|---|---|---|
de Geus et al. [21] (plasma) | eGFR <60 mL/minute/1.73 m2 at admission | 498, of whom 7% (37) developed AKI | AKI within 7 days 0.75 ± 0.10 | AKI within 7 days 0.77 ± 0.05 |
de Geus et al. [21] (urine) | eGFR <60 mL/minute/1.73 m2 at admission | 498, of whom 7% (37) developed AKI | AKI within 7 days 0.79 ± 0.10 | AKI within 7 days 0.80 ± 0.04 |
Doi et al. [24] (urine) | AKI at admission | 274, of whom 24% (66) developed AKI | AKI within 7 days 0.60 (0.52-0.67) | AKI within 7 days 0.70 (0.63-0.75) |
Constantin et al. [26] (plasma) | AKI at admission | 56, of whom 36% (20) developed AKI | AKI within 7 days 0.96 (0.86-0.99) | AKI within 7 days 0.92 (0.85-0.97) |
Siew et al. [29] (urine) | eGFR <75 mL/minute/1.73 m2 at admission | 275, of whom 7% (18) developed AKI | AKI within 24 hours 0.77 (0.64-0.90) | AKI within 24 hours 0.71 (0.63-0.78) |
Cruz et al. [25] (plasma) | Only patients without AKI at enrollment were included in primary analyses. | |||
Makris et al. [30] (urine) | Only patients with sCr <1.5 mg/dL (133 μmol/L) on entry were included in primary analysis. | |||
Endre et al. [22] (urine) | Only patients without AKI on entry were included in primary analysis. | |||
Metzger et al. [28] (urine) | Only patients without AKI within 48 hours of admission were included in primary analysis. | |||
MÃ¥rtensson et al. [27] (plasma) | Only patients with eGFR >60 mL/minute/1.73 m2 on entry were included in primary analysis. | |||
MÃ¥rtensson et al. [27] (urine) | Only patients with eGFR >60 mL/minute/1.73 m2 on entry were included in primary analysis. | |||
Kokkoris et al. [31] (plasma) | Only patients with known baseline sCr <1.6 mg/dL (141 μmol/L) were included in primary analysis. |